This trade activity should not be overlooked: Neumora Therapeutics Inc (NMRA)

With 1.29 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.18 million shares. The 52-week range on NMRA shows that it touched its highest point at $21.00 and its lowest point at $1.60 during that stretch. It currently has a 1-year price target of $12.99. Beta for the stock currently stands at 2.48.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NMRA was down-trending over the past week, with a drop of -4.05%, but this was down by -21.70% over a month. Three-month performance dropped to -83.04% while six-month performance fell -85.57%. The stock lost -91.18% in the past year, while it has lost -84.34% so far this year. A look at the trailing 12-month EPS for NMRA yields -1.85 with Next year EPS estimates of -1.61. For the next quarter, that number is -0.42. This implies an EPS growth rate of 56.61% for this year and -2.42% for next year.

Float and Shares Shorts:

At present, 160.48 million NMRA shares are outstanding with a float of 55.85 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NMRA since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.48706 being high and -$1.59468 being low. For NMRA, this leads to a yearly average estimate of -$1.57511. Based on analyst estimates, the high estimate for the next quarter is -$0.39 and the low estimate is -$0.47. The average estimate for the next quarter is thus -$0.44.